company background image
PARN

Parnell Pharmaceuticals HoldingsOTCPK:PARN.F Stock Report

Last Price

US$0.0002

Market Cap

US$5.9k

7D

0%

1Y

-99.9%

Updated

24 Jan, 2022

Data

Company Financials
PARN.F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

PARN.F Stock Overview

Parnell Pharmaceuticals Holdings Ltd, a veterinary pharmaceutical company, focuses on developing, manufacturing, and commercializing various animal health solutions.

Parnell Pharmaceuticals Holdings Competitors

Merck

NYSE:MRK

US$199.1b

Zoetis

NYSE:ZTS

US$94.7b

Phibro Animal Health

NasdaqGM:PAHC

US$810.1m

Novartis

SWX:NOVN

CHF171.7b

Price History & Performance

Summary of all time highs, changes and price drops for Parnell Pharmaceuticals Holdings
Historical stock prices
Current Share PriceUS$0.0002
52 Week HighUS$0.89
52 Week LowUS$0.0001
Beta0
1 Month Change100.00%
3 Month Changen/a
1 Year Change-99.94%
3 Year Change-99.91%
5 Year Change-99.98%
Change since IPO-100.00%

Recent News & Updates

Shareholder Returns

PARN.FUS PharmaceuticalsUS Market
7D0%-3.7%-5.8%
1Y-99.9%3.0%4.2%

Return vs Industry: PARN.F underperformed the US Pharmaceuticals industry which returned 5.3% over the past year.

Return vs Market: PARN.F underperformed the US Market which returned 4.2% over the past year.

Price Volatility

Is PARN.F's price volatile compared to industry and market?
PARN.F volatility
PARN.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement6.7%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.4%

Stable Share Price: Insufficient data to determine PARN.F's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine PARN.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009n/aBrad McCarthyhttps://www.parnell.com

Parnell Pharmaceuticals Holdings Ltd, a veterinary pharmaceutical company, focuses on developing, manufacturing, and commercializing various animal health solutions. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for improving cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product aids in the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection.

Parnell Pharmaceuticals Holdings Fundamentals Summary

How do Parnell Pharmaceuticals Holdings's earnings and revenue compare to its market cap?
PARN.F fundamental statistics
Market CapAU$8.33k
Earnings (TTM)-AU$7.18m
Revenue (TTM)AU$28.99m

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PARN.F income statement (TTM)
RevenueAU$28.99m
Cost of RevenueAU$11.60m
Gross ProfitAU$17.39m
ExpensesAU$24.57m
Earnings-AU$7.18m

Last Reported Earnings

Dec 31, 2019

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did PARN.F perform over the long term?

See historical performance and comparison

Valuation

Is Parnell Pharmaceuticals Holdings undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Parnell Pharmaceuticals Holdings is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Parnell Pharmaceuticals Holdings has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is Parnell Pharmaceuticals Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Parnell Pharmaceuticals Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Parnell Pharmaceuticals Holdings performed over the past 5 years?

14.8%

Historical Pharmaceuticals & Biotech annual earnings growth


Earnings and Revenue History

Quality Earnings: Insufficient data to determine if PARN.F has high quality earnings.

Growing Profit Margin: Insufficient data to determine if PARN.F's profit margins have improved over the past year.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if PARN.F's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare PARN.F's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if PARN.F's earnings growth over the past year exceeded the Pharmaceuticals industry average.


Return on Equity

High ROE: PARN.F has a negative Return on Equity (0%), as it is currently unprofitable.


Financial Health

How is Parnell Pharmaceuticals Holdings's financial position?


In this section we usually analyse Parnell Pharmaceuticals Holdings's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Parnell Pharmaceuticals Holdings has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Dividend

What is Parnell Pharmaceuticals Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PARN.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PARN.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PARN.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PARN.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PARN.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

11.9yrs

Average board tenure


CEO

Brad McCarthy (45 yo)

12yrs

Tenure

Mr. Brad R. McCarthy, CPA, has been the Chief Financial Officer of Parnell Pharmaceuticals Holdings Ltd. since February 2010, Chief Executive Officer since January 9, 2018 and Chief Accounting Officer and...


Board Members

Experienced Board: PARN.F's board of directors are seasoned and experienced ( 11.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 40.7%.


Top Shareholders

Company Information

Parnell Pharmaceuticals Holdings Ltd's employee growth, exchange listings and data sources


Key Information

  • Name: Parnell Pharmaceuticals Holdings Ltd
  • Ticker: PARN.F
  • Exchange: OTCPK
  • Founded: 2009
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$5.923k
  • Shares outstanding: 29.62m
  • Website: https://www.parnell.com

Number of Employees


Location

  • Parnell Pharmaceuticals Holdings Ltd
  • Century Estate
  • Unit 4
  • Alexandria
  • New South Wales
  • 2015
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/24 23:20
End of Day Share Price2022/01/14 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.